Atlas Trials

Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin

Clinical trial NCT00766025 · COMPLETED

Trial details

NCT number
NCT00766025
Sponsor
AstraZeneca
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
CYP2C19 PoorExtensive Metabolizers
Start date
2008-09-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.